Unique ID issued by UMIN | UMIN000029833 |
---|---|
Receipt number | R000034080 |
Scientific Title | Factors Associated with the Efficacy of Intravenous Chlorpromazine for Delirium in Patients with Terminal Cancer |
Date of disclosure of the study information | 2017/11/05 |
Last modified on | 2017/11/05 22:02:08 |
Factors Associated with the Efficacy of Intravenous Chlorpromazine for Delirium in Patients with Terminal Cancer
the Efficacy of Intravenous Chlorpromazine for Delirium
Factors Associated with the Efficacy of Intravenous Chlorpromazine for Delirium in Patients with Terminal Cancer
the Efficacy of Intravenous Chlorpromazine for Delirium
Japan |
delirium
Psychiatry |
Malignancy
NO
The objective of the study was to evaluate factors associated with the efficacy and safety of intravenous chlorpromazine for the treatment of non-reversible delirium in end-stage cancer patients.
Safety,Efficacy
The primary outcome of this study was identification of factors that are associated with intravenous chlorpromazine efficacy based on the comparison between clinically relevant responders and non-responders.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
This study focused on 97 patients who received intravenous administration of chlorpromazine as a symptomatic treatment of non-reversible delirium
15 patients met the exclusion criteria. The exclusion criteria included 1) the consent of intravenous administration of chlorpromazine was not obtained from their families (3 patients), 2) psychiatric disorder prohibiting communication before the onset of delirium (7 patients), 3) presence of brain tumor in the lower cortex that is contraindicated (5 patients).
97
1st name | |
Middle name | |
Last name | Hideaki Hasuo |
Kansai Medical University
Department of Psychosomatic Medicine
Shinmachi 2-5-1, Hirakata, Osaka
072-804-0101
hasuohid@hirakata.kmu.ac.jp
1st name | |
Middle name | |
Last name | Hideaki Hasuo |
Kansai Medical University
Department of Psychosomatic Medicine
Shinmachi 2-5-1, Hirakata, Osaka
072-804-0101
hasuohid@hirakata.kmu.ac.jp
Kansai Medical University
Kansai Medical University
Self funding
NO
2017 | Year | 11 | Month | 05 | Day |
Unpublished
NuDESC total score was significantly improved on day 3 after intravenous chlorpromazine. The chlorpromazine efficacy rate on day 3 was 0.48 (CI: 0.38-0.58). Based on the criteria of clinically relevant efficacy, the study subjects were classified into 47 responders and 50 non-responders. The responders demonstrated significantly higher hyperactive delirium rate, and higher long prognosis rate , compared with the nonresponders. Multivariable logistic regression analysis determined two relevant factors associated with intravenous chlorpromazine efficacy, which were hyperactive delirium (odds ratio : 6.25, CI: 1.14-34.5), prognosis longer than 2 weeks (odds ratio : 17.49, CI: 4.88-62.7).
By 3 days after the initial administration, 12 patients dropped out due to death (2 patients), blood pressure decreasing episode during administration (3 patients), addition of intravenous administration of benzodiazepine due to delirium progression (5 patients), acute akathisia (1 patient), and administration refusal (1 patient).
Completed
2015 | Year | 06 | Month | 01 | Day |
2015 | Year | 06 | Month | 01 | Day |
2017 | Year | 09 | Month | 30 | Day |
2017 | Year | 09 | Month | 30 | Day |
2017 | Year | 09 | Month | 30 | Day |
2017 | Year | 12 | Month | 31 | Day |
We retrospectively evaluated 97 end-stage cancer patients that received intravenous chlorpromazine for the treatment of non-reversible delirium.
2017 | Year | 11 | Month | 05 | Day |
2017 | Year | 11 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034080
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |